Research Analysts Offer Predictions for VKTX Q1 Earnings

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Investment analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Viking Therapeutics in a report issued on Thursday, February 12th. HC Wainwright analyst J. Pantginis expects that the biotechnology company will post earnings per share of ($0.58) for the quarter. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for Viking Therapeutics’ Q2 2026 earnings at ($0.64) EPS, Q3 2026 earnings at ($0.72) EPS and FY2026 earnings at ($2.75) EPS.

Other equities analysts have also issued reports about the stock. Morgan Stanley reiterated an “overweight” rating and issued a $99.00 target price on shares of Viking Therapeutics in a report on Thursday. B. Riley Financial raised Viking Therapeutics to a “strong-buy” rating in a research report on Thursday, October 23rd. JPMorgan Chase & Co. decreased their target price on shares of Viking Therapeutics from $80.00 to $75.00 and set an “overweight” rating on the stock in a research report on Friday, October 24th. Zacks Research cut shares of Viking Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 20th. Finally, Cantor Fitzgerald set a $105.00 target price on Viking Therapeutics in a research report on Thursday, October 23rd. Three equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $87.80.

Viking Therapeutics Stock Down 4.9%

Shares of NASDAQ:VKTX opened at $29.00 on Monday. Viking Therapeutics has a 52-week low of $18.92 and a 52-week high of $43.15. The business has a fifty day moving average of $32.95 and a two-hundred day moving average of $32.55. The stock has a market cap of $3.35 billion, a P/E ratio of -9.12 and a beta of 0.76.

Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings results on Wednesday, February 11th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.49). During the same quarter last year, the firm posted ($0.32) earnings per share.

Insider Buying and Selling

In related news, CEO Brian Lian sold 233,409 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $32.96, for a total transaction of $7,693,160.64. Following the sale, the chief executive officer directly owned 2,499,291 shares in the company, valued at approximately $82,376,631.36. This represents a 8.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Marianna Mancini sold 57,661 shares of Viking Therapeutics stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $32.98, for a total transaction of $1,901,659.78. Following the completion of the transaction, the chief operating officer owned 409,190 shares of the company’s stock, valued at $13,495,086.20. This represents a 12.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 364,731 shares of company stock valued at $12,053,627. Corporate insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Ameriprise Financial Inc. lifted its stake in Viking Therapeutics by 41.8% during the third quarter. Ameriprise Financial Inc. now owns 2,092,840 shares of the biotechnology company’s stock worth $55,000,000 after purchasing an additional 616,526 shares during the last quarter. Two Sigma Investments LP boosted its stake in Viking Therapeutics by 58.7% in the third quarter. Two Sigma Investments LP now owns 2,085,487 shares of the biotechnology company’s stock valued at $54,807,000 after acquiring an additional 771,704 shares in the last quarter. Geode Capital Management LLC boosted its stake in Viking Therapeutics by 24.0% in the fourth quarter. Geode Capital Management LLC now owns 1,994,509 shares of the biotechnology company’s stock valued at $70,183,000 after acquiring an additional 385,903 shares in the last quarter. Norges Bank purchased a new position in shares of Viking Therapeutics during the second quarter worth about $46,846,000. Finally, BNP Paribas Financial Markets increased its position in shares of Viking Therapeutics by 536.3% during the fourth quarter. BNP Paribas Financial Markets now owns 992,695 shares of the biotechnology company’s stock worth $34,923,000 after purchasing an additional 836,686 shares in the last quarter. Hedge funds and other institutional investors own 76.03% of the company’s stock.

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.